BOSTON – Although several medications are approved to treat attention-deficit/hyperactivity disorder (ADHD), some individuals experience limited benefits from the drugs or develop side effects from their use. A recent clinical trial published in the Journal of Clinical Psychiatry by investigators at Massachusetts General Hospital (MGH), a founding member of Mass…Read More
Related Posts
Palisade Bio Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148…
Carlsbad, CA and Shanghai, China, April 05, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. PALI ("Palisade" or the "Company"), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)…
CMS Increases Outpatient Payment for Barostim Procedure
MINNEAPOLIS, Nov. 03, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, announced today that Centers for Medicare and Medicaid Services (CMS) has reassigned the…
No 2 House Republican Steve Scalise returns to the Capitol after his blood cancer diagnosis
WASHINGTON (AP) -- Rep. Steve Scalise, the No. 2 House Republican, returned to the U.S. Capitol on Thursday for the first time since being diagnosed with a blood cancer known…
